Abstract

ROLE OF MONOCLONAL ANTIBODIES IN THE TREATMENT OF COVID-19: A REVIEW

Manali Mangesh Gurav*

ABSTRACT

This review examines the potential use of monoclonal antibodies for the prevention and treatment of COVID-19 infection. Coronaviruses are a distinct group of viruses that infect a veriety of animal and can cause mild to severe respiratory infections in humans. For more than a decade, monoclonal antibodies (mAbs) have helpful tools that have expanded our biological knowledge. This study indicates the therapeutic approach and promise of monoclonal antibody therapy to treat Covid-19 infection. Because the U.S. Food and Drug administration (FDA) recently approved the emergency use of Neutralizing monoclonal antibodies in non- hospitalized patients with mild to moderate COVID-19. The growing demand for monoclonal antibodies (mAbs) for diagnostic and therapeutic applictions has given rise to the development of large-scale manufacturing processes with enhancement in production. Due to their therapeutic flexibility, monoclonal antibodies (mAbs) make up the majority of candidate proteins currently in clinical development. This review includes antibody-based immunotherapy using human monoclonal antibodies targeting the protein region of the SARS-CoV-2 virus, in particular the spike protein region.

Keywords: Monoclonal antibodies, SARS-CoV-2, Hybridoma technique, Spike protein, Immunotherapy.